News

Zymeworks Shares Insight on Upcoming Investor Engagements

Zymeworks Shares Insight on Upcoming Investor Engagements

Explore Zymeworks' Upcoming Investor Conferences

Zymeworks Inc. is excited to participate in several important investor conferences, showcasing its commitment to innovation in biotechnology. This Vancouver-based company specializes in developing novel biotherapeutics aimed at addressing challenging medical conditions, including cancer and autoimmune diseases.

Stifel Healthcare Conference Participation

During the Stifel Healthcare Conference, Zymeworks’ management team will engage in one-on-one meetings to share insights regarding their advancements and upcoming projects. This conference is scheduled for November 11, 2025, and will take place in New York City. Zymeworks is enthusiastic about connecting with investors who share their vision for pioneering healthcare solutions.

Jefferies London Healthcare Conference Attendance

Following the Stifel event, Zymeworks will also participate in the Jefferies London Healthcare Conference from November 17 to 19, 2025. This conference is another opportunity for Zymeworks to discuss its innovative pipeline of biotherapeutics and engage with international investors. These meetings are crucial for the company to highlight their ongoing projects and strategic direction.

About Zymeworks Inc.

Zymeworks Inc. is a dynamic clinical-stage biotechnology firm recognized for its unique approach to developing multifaceted biotherapeutics that can specifically target difficult conditions like cancer, inflammation, and autoimmune disorders. With a dedication to making a significant impact on patients' lives, Zymeworks strives to maximize the efficacy and impact of healthcare solutions.

Innovative Therapeutic Platforms

The company is particularly proud of its proprietary Azymetric™ technology, which led to the creation of zanidatamab, a bispecific antibody targeting HER2. This groundbreaking treatment has received multiple key approvals, marking it as a significant advancement in the treatment landscape for patients with HER2-positive biliary tract cancer. Zanidatamab's ability to dual-target HER2 puts Zymeworks at the forefront of targeted cancer therapies.

Robust Pipeline and Future Plans

Zymeworks continues to build a strong pipeline of wholly-owned product candidates, focusing on innovative antibody drug conjugates and multispecific antibody therapeutics. The company is currently recruiting participants for a Phase 1 study on ZW191, and ZW251 is anticipated to enter clinical trials shortly. These advancements underscore Zymeworks’ commitment to leading-edge biotechnology and addressing unmet medical needs effectively.

Collaborative Partnerships

In addition to developing internal therapies, Zymeworks has forged strategic partnerships with various biopharmaceutical companies, enhancing its ability to innovate and expand its therapeutic offerings. These collaborations are essential to leverage their platforms and bring transformative treatments to market.

Contact Information for Inquiries

For those interested in learning more about Zymeworks' initiatives and strategies, the company encourages inquiries:

Investor inquiries:

Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:

Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

Frequently Asked Questions

What is the primary focus of Zymeworks Inc.?

Zymeworks Inc. specializes in developing innovative biotherapeutics for difficult-to-treat diseases, including cancer and autoimmune disorders.

What upcoming conferences will Zymeworks participate in?

Zymeworks will participate in the Stifel Healthcare Conference and the Jefferies London Healthcare Conference in November 2025.

What is zanidatamab?

Zanidatamab is a HER2-targeted bispecific antibody developed by Zymeworks, recently approved for treating HER2-positive biliary tract cancer.

How is Zymeworks advancing its product pipeline?

The company is actively recruiting for clinical trials and continues to explore new therapeutic candidates to address unmet medical needs.

What partnerships does Zymeworks have?

Zymeworks collaborates with global biopharmaceutical companies to enhance its research and development efforts for biotherapeutics.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 7

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 10

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 5

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 9

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 6

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading

Top 5 Most Recently Viewed Articles

Honeywell's Bold Strategic Overhaul and 2026 Separation Plans

Updated Category News Views 726

Honeywell's Strategic Restructuring Initiative Honeywell International Inc. HON has recently announced its intent to evaluate strategic alternatives for two of its logistics-centric business divisions as it gears up for a significant corporate realignment scheduled for 2026. This decision is part of a broader effort to streamline operations and sharpen the company's focu

Continue Reading
Market Update: Canadian Stocks Experience Slight Decline Today

Updated Category News Views 307

Making Sense of the Latest Moves in the Canadian Stock Market Canada’s stock market slipped on Tuesday, with a handful of key sectors doing most of the dragging. Energy, Consumer Discretionary, and Telecom names led the weakness, leaving investors weighing whether this was a brief step back or a sign of a deeper pause. The tone wasn’t uniformly negative,...

Continue Reading
Buyers Edge Platform Partners with Allmanhall to Boost Growth

Updated Category News Views 266

Strategic Partnership Strengthens Market Presence Buyers Edge Platform, a renowned leader in foodservice procurement technology, has recently announced a significant partnership with allmanhall, a distinguished UK-based food procurement specialist. This collaboration not only enhances Buyers Edge Platform's foothold in the UK but also amplifies its capabilities in...

Continue Reading
Daikin Marks 100 Years of HVAC Excellence and Innovation

Updated Category News Views 199

Daikin Celebrates 100 Years of Innovation Daikin Industries, Ltd., a global leader in Heating, Ventilation, Air Conditioning, and Refrigeration (HVAC&R), is celebrating its remarkable centennial anniversary. Throughout this century, Daikin has consistently demonstrated a commitment to innovation and sustainability, impacting indoor comfort across various climates....

Continue Reading
Understanding Share Capital and Voting Rights at Nexans S.A.

Updated Category News Views 127

Insights into Share Capital and Voting Rights The insights regarding share capital and voting rights are crucial for shareholders and potential investors in Nexans S.A. Comprehending these elements can significantly enhance one's perception of their investment's value and voting power within the company. Date of Statement This report reflects the share capital status as...

Continue Reading